L&C Bio Co

L&C Bio Co Capital Expenditures

The Capital Expenditures (CapEx) of L&C Bio Co (290650.KQ) as of Oct 20, 2026 is -17.04 B KRW. In the previous year, Capital Expenditures (CapEx) was -5.35 B KRW — a change of 218.44% (lower).

Capital Expenditures

-17.04 BKRW

YoY

218.44%

Last updated:

Capital Expenditures (CapEx) of L&C Bio Co is 2025 -17.04 B KRW. Capital Expenditures (CapEx) of L&C Bio Co was 2024 -5.35 B KRW. It decreases by 218.44% lower compared to the previous year.

The L&C Bio Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-4.74 B KRW
Jan 1, 2019
-1.96 B KRW
Jan 1, 2020
-3.02 B KRW
Jan 1, 2021
-10.25 B KRW
Jan 1, 2022
-37.53 B KRW
Jan 1, 2023
-24.98 B KRW
Jan 1, 2024
-5.35 B KRW
Jan 1, 2025
-17.04 B KRW
The L&C Bio Co Capital Expenditures history
YEARCapital ExpendituresYoY
-17.04 BKRW+218.44%
-5.35 BKRW-78.59%
-24.98 BKRW-33.43%
-37.53 BKRW+266.12%
-10.25 BKRW+239.85%
-3.02 BKRW+54.10%
-1.96 BKRW-58.70%
-4.74 BKRW+1,560.88%
-285.34 MKRW-60.14%
-715.85 MKRW+159.27%
-276.10 MKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

L&C Bio Co Stock analysis

What does L&C Bio Co do? L&C BIO Co., Ltd. generates revenue by manufacturing and selling human tissue transplant materials designed for tissue repair and filler applications. The company also produces and sells human tissue-based medical devices and Cosmeceuticals, which serve various surgical needs including vascular, plastic, and general surgeries. The firm operates as a developer of soft tissue, allografts, and medical devices, with its products utilized in multiple medical procedures. This business model focuses on providing essential biological materials and devices to the healthcare sector through its core product lines. L&C Bio Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about L&C Bio Co stock

Capital Expenditures (CapEx) of L&C Bio Co is -17.04 B KRW in 2025.

Capital Expenditures (CapEx) of L&C Bio Co changed from -5.35 B KRW to -17.04 B KRW, representing a 218.44% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) L&C Bio Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s L&C Bio Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — L&C Bio Co

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — L&C Bio Co